An underused opportunity to introduce ACE inhibitors and influence prognosis: observational study of patients undergoing aortic surgery by Muttardi, K et al.
XML Template (2013) [2.5.2013–5:56pm] [1–7]
//blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/SHRJ/Vol00000/130012/APPFile/SG-SHRJ130012.3d (SHR) [PREPRINTER stage]
RESEARCH
An underused opportunity to
introduce ACE inhibitors and
influence prognosis: observational
study of patients undergoing
aortic surgery
Kayria Muttardi1 . Ali Haydar2 . Chee Kiang Phua1 .
Neil Chapman3 . Michael Jenkins1 . Nicholas JW Cheshire1 .
Colin D Bicknell1
1Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London, UK; 2Department of Radiology, Imperial College
London, London, UK; 3International Centre for Circulatory Health, Imperial College London, London, UK
Correspondence to: Colin Bicknell. Email: colin.bicknell@imperial.ac.uk
Summary
Objective: To asses whether Angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs) are underused in patients with
aortic disease due to concerns regarding flow limiting (>70%) renal artery
stenosis (RAS).
Design: A prospective analysis of patients admitted for aortic surgery was
performed (January–July 2009). Co-morbidity, ACEI/ARB use and renal
function were recorded. Computerised tomography (CT) angiograms were
reviewedby a single blinded radiologist for the presence and severity of RAS.
Setting: St Mary’s Hospital, Vascular Unit, Imperial College Healthcare NHS
Trust, London, UK.
Participants: 75 randomly selected patients admitted to our vascular unit including
elective and emergency admissions.
Main outcome measures: Indications for ACEI therapy were identified as determined
by the National Institute of Health and Clinical Excellence (NICE) guidance.
The ratio of the measurement distal to the stenosis and at the area of max-
imal stenosis onCT angiographywere used to calculate the percentageRAS.
Results: 60 patients were identified (15 patients excluded due to previously
modified renal vessels). Themedian age was 73 [interquartile range 68, 77].
Their underlying aortic disease included 52 (87%) aortic aneurysm, 6 (10%)
with aortic dissection, 1 (1.7%) patient with occlusive disease and 1 (1.7%)
patient with mycotic disease. Overall, 56/60 (93%) patients had at least one
indication for ACEI therapy. 33/60 (55%) of patients were already receiving
ACEI. CT angiogram examination demonstrated 17/60 (28%) patients have
RAS of some degree, of which only 9/60 (15%) have flow limiting RAS.
Conclusion: A large proportion of aortic patients do not receive ACEI/ARB therapy
despite definite indications and a low prevalence of flow-limiting RAS is
low. After the exclusion of RAS at angiography, careful introduction of
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ACEI therapy with appropriate monitoring could be considered for many
more patients.
Introduction
Medical therapy is of vital importance for the
long-term survival and prognosis of atheroscler-
otic patients. However, despite there being good
evidence to support the use of aspirin and statins
in vascular disease, it has been shown that these
are often not well utilized in vascular patients.
The BASIL trial1 showed that almost 40% of vas-
cular patients were not receiving antiplatelet ther-
apy and that only a third were taking statins.
Similar figures were echoed by the EVAR II trial.2
There has also been growing evidence to sup-
port the use of angiotensin-converting enzyme
inhibitors (ACEI) in patient cohorts similar to
those enrolled in the above-mentioned trials. The
HOPE study3 demonstrated a relative risk survival
advantage of 22% in patients with cardiovascular
risk factors, showing benefits beyond those gained
from blood pressure control alone. Analogous find-
ings have been shown in the PROGRESS study4
with a reduced stroke risk of 28% and a 26% reduc-
tion in major coronary events with perindopril.
Additional evidence for ACEI benefits in heart fail-
ure and diabetes-associated microalbuminuria
have also been demonstrated.
The American Heart Association (AHA) guide-
lines5 for the management of patients with periph-
eral arterial disease (PAD) now recommend the use
of ACEI in patients with asymptomatic PAD owing
to its cardiovascular benefits. Despite this large
body of evidence, there still appears to be some
reluctance to use ACEI in arterial patients due to
the concern over renal artery stenosis (RAS). ACEI
are contraindicated in bilateral flow limiting (FL)
RAS and unilateral FL RAS with a single function-
ing kidney. Impaired renal function per se is not a
contraindication to the use of ACEI.
Our aim was to determine (1) the number of
patients undergoing aortic surgery with an indi-
cation for ACEI therapy, (2) the prevalence of RAS
in this population and (3) the proportion of
patients who were already on ACEI prior to sur-
gery and therefore estimate the percentage of
patients who would benefit from introducing
ACEI therapy at the time of assessment and treat-
ment of their aortic disease.
Methods
Patient selection
We prospectively studied 75 randomly selected
patients from January 2009 to July 2009 that
were admitted to our vascular unit including
elective and emergency admissions. The inclusion
criteria were anyone admitted with aortic occlu-
sive and aneurismal disease including infrarenal,
juxtarenal and thoracoabdominal aneurysms.
Fifteen patients with previous hybrid grafts,
branched stents and renal transplants had to be
excluded from the trial as the renal vessels in these
patients were previously modified.
Data collection
Patient demographics were collected for each of
these patients including age, sex, ethnicity, type of
aneurismal disease and indications for ACEI
therapy.
Indications for ACEI therapy are listed below
and are as determined by the National Institute of
Health and Clinical Excellence (NICE) guidance.
. Stroke
. Myocardial infarction (MI)/Ischaemic heart
disease (IHD)
. Hypertension (HTN)
. Diabetes mellitus (DM)
. Congestive cardiac failure (CCF)
Admission creatinine values were also recorded
for each patient as a surrogate for renal function.
CT angiography interpretation
In order to assess the presence of RAS, preopera-
tive CT scans were analysed. The CT scans were
carried out with Siemens 64-CT scanner by a
single radiologist according to the CTA protocol
for St Mary’s Hospital, Paddington, UK. The fol-
lowing is a summary of the CTA protocol used:
. To obtain optimal images of the kidney
hilum, the patient is required to hold his/
her breath for 30–40 s.
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. The region of interest for imaging extends
from the suprarenal abdominal aorta to the
bifurcation of the iliac artery.
. A narrow collimation of 1–3mm and a pitch
up to 2 are used as parameters for helical CT
scanning.
. For the evaluation of renal hilum in renal
stenosis, a 1-mm interscan spacing is ideal.
Images are reconstructed equally through-
out the data set.
A single-blinded radiologist analysed images.
Maximum intensity projection (MIP) and volume
rendering techniques were used in the evaluation
of RAS. Measurements of the vessel distal to the
stenosis and at the area of maximal stenosis were
taken. The ratio was obtained and this constituted
an estimate measurement of the RAS. We defined
flow-limiting RAS as stenosis of 70% or more.
Statistical analysis
Data analyses was performed to determine which
patients were already on ACEI/ARBS, how many
would benefit from them and how many should
be excluded because of RAS. Correlation coeffi-
cients were calculated to assess the relationship
between kidney size, creatinine and the presence
of RAS.
Results
Sixty patients were identified (median age 73
[interquartile range 68, 77]) of which 51 were
Caucasian. Their underlying aortic disease
included 52 (87%) aortic aneurysm, 6 (10%) with
aortic dissection, 1 (1.7%) patient with occlusive
disease and 1 (1.7%) patient with mycotic disease
(see Table 1).
Analysis of our patient demographic demon-
strated that 56 (93%) patients overall had at least
one indication for ACEI therapy (see Figure 1).
Eighty-eight per cent had HTN, 45% IHD, 16.7%
stroke, 11.7% DM and 6.7% with CCF.
Furthermore, patients often had more than one
indication for being on an ACEI/angiotensin
receptor blocker (ARB) with 18.3% of patients
having three or more risk factors and 52%
having two or more risk factors.
Despite these indications, only 33 (55%)
patients were receiving an ACEI (60% of hyper-
tensive patients, 60% of stroke patients, 57% of
diabetic patients, 70% of CCF patients and 59%
of IHD patients). The superimposed yellow bars
in Figure 1 demonstrate this.
Prevalence of RAS
A high proportion of patients do not have RAS.
Seventeen of 60 (28%) patients were found to have
RAS of some degree, of which 7/60 (11.7%) have
FL RAS >70% on one side. Two patients had bilat-
eral FL RAS and therefore these patients had an
absolute contraindication to ACEI therapy (see
Figure 2).
In patients with no RAS, the median creatinine
was 99mmol/L, the median right kidney size was
10.2 cm and the median left kidney size was
10.5 cm.
We also looked to see whether there is any cor-
relation between renal function, kidney size and
Table 1.
Patient demographics and co-morbidities.
Patient demographics
AgeþxIQ 73 (68, 77)
Male 51/60 (85%)
Caucasian 56/60 (93%)
Aortic disease
Aortic aneurysm (%) 52/60 (87%)
Aortic dissections (%) 6/60 (10%)
Occlusive disease (%) 1/60 (1.7%)
Mycotic disease (%) 1/60 (1.7%)
Co-morbidities
Stroke 10/60 (16.7%)
Myocardial infarction/Ischaemic
heart disease
27/60 (45%)
Congestive cardiac failure 4/60 (6.7%)
Diabetes mellitus 7/60 (11.7%)
Hypertension 53/60 (88%)
Renal function
Creatinine mmol/litre
Median (interquartile range) 101 (81, 124)
ACEI/ARB on admission 33/60 (55%)
Side effect/intolerance of ACEI 1/60 (1.7%)
ACEI: angiotensin-converting enzyme inhibi-
tor; ARB: angiotensin receptor blocker.
Use of ACEI/ARB therapy in aortic patients
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the presence of RAS.We analysed the data from 19
kidneys (15 kidneys unilateral RAS and four kid-
neys bilateral RAS) and found that the presence of
RAS did not correlate well with simple markers of
renal function such as kidney size and creatinine
(see Figures 3 and 4).
Discussion
The prognostic effects of ACEI have been credibly
demonstrated in patients with IHD, HTN, Stroke,
CCF andDM in numerous large outcome studies.6
Indications for ACEI therapy and the proportion of patients 
on treatment
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Figure 1. Indications of ACEI therapy in the populations studied and the proportion of these patients who are receiving
ACEI therapy. Fifty-six of 60 patients (93%) had at least one indication for ACEI therapy (88% had hypertension, 45%
ischaemic heart disease, 16.7% stroke, 11.7% Diabetes mellitus and 6.7% with congestive cardiac failure). The super-
imposed bars in yellow represent actual ACEI use on admission of which in total only 33/60 (55%) were receiving it
despite one or more indications. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.
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Figure 2. Prevalence of RAS in our population. Forty-three of 60 (72%) had no RAS, 17/60 (28%) patients had RAS of
some degree of which 8/60 (13%) had unilateral stenosis of >70% severity and 7/60 (12%) had unilateral flow limiting
stenosis. Only 2/60 (3%) patients had bilateral flow limiting RAS. RAS: renal artery stenosis.
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Furthermore, there is some evidence to suggest
that patients taking ACEI have a reduced risk of
rupture from aortic aneurysms, unlike other anti-
hypertensive agents.7 This is supported by studies
in both mice models and patients with Marfan’s,
which have shown that the use of ACEI slows
down the rate of aortic root growth.8 This is
thought to be due to ACEI vascular anti-
inflammatory effects and inhibition of matrix
metalloproteinases.7
Although this study looked at 60 patients, the
patient demographic appears to be representative
of the population we wish to study. This is backed
by the consistency of our demographic data with
the EVAR trial baseline characteristics.2,9 Our
results confirm that a large proportion of patients
with aortic disease (93%) have at least one indica-
tion for ACEI therapy. This is fully expected due
to the well-known strong correlation between
aneurysmal aortic disease and vascular risk
factors such as HTN, IHD and diabetes.
However, despite the indications, only 55% of
patients were receiving an ACEI. This raises con-
cern along with data from EVAR II,2 which
showed that only 58% of high-risk aneurysm
patients were taking aspirin and 41.8% taking sta-
tins. We did not analyse data on statin and aspirin
use on admission, which retrospectively would
have been useful.
Many factors may influence the underuse of
medical therapy in vascular patients including
patient autonomy and difficulties with polyphar-
macy. In addition, the degree of primary care con-
tact with the patient would have a significant
effect. There is also the issue of side effects par-
ticularly cough with ACEI; however, only one of
our patients had a known side effect to ACEI.
Although this does not explain the low rates of
aspirin and statin use in vascular patients, one
theory for the underuse of ACEI/ARB in these
0
20
40
60
80
100
120
140
160
180
200
0 20 40 60 80 100
Cr
ea
tin
in
e 
 u
m
o
l/ 
L
% stenosis of renal artery
Correlation of Creatinine with Renal artery stenosis
Figure 3. Scatterplot showing correlation between creatinine and RAS. Data based on 17 patients with RAS (15 with
unilateral and 2 with bilateral RAS). This demonstrates that there is a poor correlation between creatinine and RAS.
Correlation coefficient, 0.07. RAS: renal artery stenosis.
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Figure 4. Scatterplot showing correlation between kidney size and RAS. Data based on 17 patients with RAS (15 with
unilateral and 2 with bilateral RAS). This demonstrates that there is poor correlation between creatinine and RAS.
Correlation coefficient, 0.2. RAS: renal artery stenosis.
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patients may be the concern over the possible
presence of RAS. ACEI are contraindicated in FL
bilateral RAS or unilateral RAS with a single func-
tioning kidney. If used in these circumstances,
ACEI can cause a reversible rise in creatinine
and acute renal failure. However, a baseline
raised creatinine alone without RAS is not in
itself a contraindication to ACEI therapy.
RAS of which 90% is atherosclerotic is the most
common primary disease of the renal arteries.10
There have been no studies looking at the pres-
ence of RAS in patients with aortic disease specif-
ically but often patients with risk factors for
atherosclerotic disease are studied. However,
haemodynamically significant RAS can be present
in patients with normal blood pressure and renal
function. Studies have demonstrated a varied
prevalence of RAS from 14% to 42% in patients
with aortic or peripheral vascular disease11–14 as
stated in Ref. 10. Our results show that 28% of our
patients have some degree of RAS. Seven (11.7%)
patients have unilateral FL RAS and 2 (3%) have
bilateral FL RAS.
Most would consider intra-arterial digital sub-
traction angiography as the standard in the diag-
noses of RAS.However, it is invasive and subject to
high inter-observer variation in assessing severity
of lesions.15Therefore, theAHAguideline2005rec-
ommends the following screening tests for RAS.
. Duplex ultrasonography
. CT angiography
. MRA
. Catheter angiography as diagnostic test to
establish diagnosis of RAS when clinical
index of suspicion is high and results of
non-invasive tests are inconclusive
CTangiography has been shown to have a sen-
sitivity of 59–96% and specificity of 82–99% for
detecting significant RAS when compared to cath-
eter guided angiography.5 In our study, all CT
scans were reviewed by a single radiologist to
avoid inter-observer bias. Another important
reason for the wide prevalence estimate of RAS
in atherosclerotic patients is that some studies
use 50% as the definition for FL RAS and others
use 70%. At least 50% stenosis is required to give a
pressure drop in the renal artery; however, the
narrower the stenosis the more likely that there
is a drop, which is the rationale for using 70%
stenosis as the cut off. The AHA guidelines 2005
define haemodynamically significant stenosis as
any stenosis of 50–70% associated with a transle-
sional gradient of 20mmHg or a mean gradient
10mmHg or any 70% stenosis. As flow cannot
be measured on CT, we used 70% stenosis as our
cut off for FL disease.
We also looked at renal function and size as
predictors of RAS. There was a poor correlation
between creatinine and severity of RAS. One
explanation is that in this cohort of patients,
renal dysfunction is likely to be as a consequence
of multiple aetiologies including HTN and DM.
Nevertheless, similar findings have been reported
in several studies.16–18 Both epidemiological stu-
dies and single kidney Glomerular filtration rate
(GFR) studies found no correlation between RAS
severity and degree of renal impairment, apart
from kidneys with complete occlusion of the
renal artery where an ischaemic nephropathy usu-
ally ensues.
However, there is evidence to suggest that age
>65 and the presence of HTN are independent
predictors of RAS.19,20 Some studies have sug-
gested that renal parenchymal injury in patients
with RAS is secondary to long standing HTN. The
HTN often predates RAS and is the major factor
responsible for raised creatinine in these patients.
This is supported by single kidney GFR studies
that also demonstrate impaired renal function in
the non-affected kidney of patients with single
kidney RAS.18
Our results show that kidney size was similar
for all patients irrespective of the presence of RAS
and its severity. It may be that our sample size is
too small or that a natural history study would be
more appropriate to examine this as the evidence
from several studies has demonstrated decrease
in kidney size with FL RAS.21,22
Of the 56patientswith indications forACEI ther-
apy, three have been excluded (two due to bilateral
FL RAS and one due to side effects). This leaves 53
patients of which 33 are already receiving ACEI/
ARBs. Therefore, 20 patients (33%) should be on
an ACEI but are not currently receiving it.
Consequently, we conclude that a large proportion
of aortic patients donot receiveACEI/ARB therapy
despite definite indications and even though the
prevalence of flow-limiting RAS is low. After the
exclusion of RAS at CT angiography, careful intro-
duction of ACEI therapy with appropriate
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monitoring could be considered for many more
patients. We propose that the hospital admission
for the treatment of the underlying aortic disease
is an ideal point for the introductionofACEI, statins
and aspirin for patients who would benefit from
them.
References
1. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus
angioplasty in severe ischaemia of the leg (BASIL):
multicentre randomised controlled trial. Lancet
2005;366:1925–34
2. EVAR trial participants. Endovascular aneurysm repair and
outcome in patients unfit for open repair of abdominal aortic
aneurysm (EVAR trial 2): randomised controlled trial. Lancet
2005;365:2187–92
3. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-
converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med
2000;342:145–53
4. PROGRESS Collaborative Group. Randomised trial of a
perindopril-based blood-pressure-lowering regimen among
6105 individuals with previous stroke or transient ischaemic
attack. Lancet 2001;358:1033–41
5. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005
Practice Guidelines for the Management of Patients With
Peripheral Arterial Disease (Lower Extremity, Renal,
Mesenteric, and Abdominal Aortic) : A Collaborative Report
from the American Association for Vascular Surgery/Society
for Vascular Surgery,* Society for Cardiovascular
Angiography and Interventions, Society for Vascular
Medicine and Biology, Society of Interventional Radiology,
and the ACC/AHA Task Force on Practice Guidelines
(Writing Committee to Develop Guidelines for the
Management of Patients With Peripheral Arterial Disease):
Endorsed by the American Association of Cardiovascular
and Pulmonary Rehabilitation; National Heart, Lung, and
Blood Institute; Society for Vascular Nursing; TransAtlantic
Inter-Society Consensus; andVascular Disease Foundation.
Circulation. 2006;113:e463–e654
6. Stojiljkovic L, Behnia R. Role of renin angiotensin
system inhibitors in cardiovascular and renal protection: a
lesson from clinical trials. Curr Pharm Des 2007;13:1335–45
7. HackamDG, ThiruchelvamD, Redelmeier DA. Angiotensin-
converting enzyme inhibitors and aortic rupture: a popula-
tion-based case-control study. Lancet 2006;368:659–65
8. Moltzer E, Essers J, van Esch JH, Roos-Hesselink JW. The role
of the renin-angiotensin system in thoracic aortic aneurysms:
clinical implications. Pharmacol Ther 2011;131:50–60
9. Greenhalgh RM, Brown LC, Epstein D, et al. Endovascular
aneurysm repair versus open repair in patients with
abdominal aortic aneurysm (EVAR trial 1): randomised
controlled trial. Lancet 2005;365:2179–86
10. Zoccali C, Mallamaci F, Finocchiaro P. Atherosclerotic renal
artery stenosis: epidemiology, cardiovascular outcomes,
and clinical prediction rules. J Am Soc Nephrol
2002;13:S179–83
11. Valentine RJ, Myers SI, Miller GL, Lopez MA, Clagett GP.
Detection of unsuspected renal artery stenosis in patients
with abdominal aortic aneurysms: refined indications for
preoperative aortography. Ann Vasc Surg 1993;7:220–4
12. Olin JW,Melia M, Young JR, Graor RA, Risius B. Prevalence
of atherosclerotic renal artery stenosis in patients with
atherosclerosis elsewhere. Am J Med 1990;88:46N–51N
13. Choudhri AH, Cleland JG, Rowlands PC, Tran TL,
McCarthy M, Al-Kutoubi MA. Unsuspected renal artery
stenosis in peripheral vascular disease. BMJ
1990;301:1197–8
14. Wilms G, Marchal G, Peene P, Baert AL. The angiographic
incidence of renal artery stenosis in the arteriosclerotic
population. Eur J Radiol 1990;10:195–7
15. Leiner T, de Haan MW, Nelema PJ, et al. Contemporary
imaging techniques for the diagnosis of renal artery sten-
osis. Eur Radiol 2005;15:2219–29
16. Suresh M, Laboi P, Mamtora H, et al. Relationship of renal
dysfunction to proximal arterial disease severity in ath-
erosclerotic renovascular disease. Nephrol Dial Transplant
2000;15:631–6
17. Cheung CM, Wright JR, Shurrab AE, et al. Epidemiology of
renal dysfunction and patient outcome in atherosclerotic
renal artery occlusion. J Am Soc Nephrol 2002;13:149–57
18. Farmer CKT, Reidy J, Kalra PA, et al. Individual kidney
function before and after renal angioplasty. Lancet
1998;352:288–9
19. Addad F, Betbout F, Farhat MB, et al. Prevalence and pre-
dictors of renal artery stenosis in patients with coronary
artery disease. Int J Angiol 2005;14:81–6
20. Ghaffari S, Sohrabi B, Siahdasht RB, Pourafkari L.
Prevalence and predictors of renal artery stenosis in
hypertensive patients undergoing coronary angiography.
Hypertension Res 2009;32:1009–14
21. Guzman R, Zierler R, Isaacson A, O Bergelin R, Strandness
D. Renal atrophy and arterial stenosis. A prospective study
with duplex ultrasound. Hypertension 1994;23:346–50
22. Modrall JG, Timaran CH, Rosero EB, et al. Longitudinal
changes in kidney parenchymal volume associated with
renal artery stenting. J Vasc Surg 2012;55:774–80
 2013 The Author(s)
This is an open-access article distributed under the terms of the Creative Commons Non-commercial
Attribution License (http://creativecommons.org/licenses/by-nc/2.0/), which permits non-commercial
use, distribution and reproduction in any medium, provided the original work is properly cited.
Use of ACEI/ARB therapy in aortic patients
J R Soc Med Sh Rep 2013: 0: 1–7. DOI: 10.1177/2042533313484145 7
